Revvity Inc. stock holds above 130 dollars as analysts stick with Hold ratings

Published on 09/07/2026 at 17:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revvity Inc. stock is trading firmly above the 130 dollar mark, while a fresh consensus from brokerages keeps the shares at a Hold rating with downside to the average target price.

Labor mit Wissenschaftlerin an Sequenziergerät und Reagenzflaschen — Fotorealistisches Life-Sciences-Labor zeigt Revvity Inc. (ISIN US76155R1086) mit automatisiertem Sequenziergerät und Reagenzien, Illustration mit AI erstellt.

Revvity Inc. stock (ISIN US76155R1086) is trading at 130.24 dollars on the New York Stock Exchange as of September 4, 2026, reflecting a modest 0.30% decline on the day but a strong 34.5% gain since the start of 2026, according to MarketBeat data.

Analysts maintain Hold stance with downside to target

A fresh consensus compiled on September 7, 2026 shows that seventeen brokerages covering Revvity Inc. stock maintain an average recommendation of Hold, with thirteen firms rating the shares as Hold and four as Buy, according to MarketBeat. The average one-year price target stands at 114.77 dollars, implying around 11.9% downside from the current level of 130.24 dollars as of September 4, 2026.

Within this framework, one notable move comes from KeyCorp, which recently raised its target price for Revvity Inc. stock from 125.00 dollars to 165.00 dollars and assigned an overweight rating, signaling confidence in the company’s longer-term growth prospects despite the broader Hold consensus. Other research houses such as Wolfe Research, Zacks Research and Evercore have shifted their views over recent months, contributing to the mixed but generally cautious analyst backdrop.

Latest quarterly figures beat expectations but revenue edges lower

Revvity Inc. reported its most recent quarterly results on August 4, 2026, delivering earnings per share of 1.41 dollars, which exceeded the analyst consensus estimate of 1.21 dollars by 0.20 dollars, according to MarketBeat. The company generated revenue of 729.69 million dollars in the quarter, surpassing expectations of 702.96 million dollars and highlighting the resilience of its life sciences and diagnostics franchise.

Despite the earnings beat, the top line declined slightly, with quarterly revenue down 1.3% compared with the same quarter a year earlier, when Revvity Inc. earned 1.18 dollars per share. That combination of margin strength and modest revenue pressure helps explain why the market rewards the stock with a premium valuation while analysts remain cautious about the growth trajectory.

For the full fiscal year 2026, Revvity Inc. has set guidance for earnings per share in the range of 5.30 to 5.40 dollars, and sell-side consensus currently centers around 5.37 dollars per share, according to MarketBeat. Relative to the trailing twelve-month earnings per share of 2.10 dollars and a price-to-earnings ratio of 62.02, the forward valuation multiple of roughly 24.25 suggests that investors expect a material improvement in profitability over the coming quarters.

Valuation, dividend and risk factors for investors

At the closing price of 130.24 dollars on September 4, 2026, Revvity Inc. stock trades at a trailing price-to-earnings ratio of 62.02, significantly above the broader market average of about 45.02 but below the healthcare sector’s average multiple of roughly 274.10, according to MarketBeat. On a price-to-book basis the shares stand at 2.01 times book value, and the company’s PEG ratio of 2.37 indicates that the valuation embeds a rich premium to expected earnings growth.

From an income perspective, Revvity Inc. pays a modest quarterly dividend that results in an annualized payout of 0.28 dollars per share and a yield of about 0.21% at the current price, with a dividend payout ratio of 13.33%, according to MarketBeat. That low payout ratio and expected future earnings of 5.89 dollars per share in the coming year suggest capacity to maintain or gradually increase distributions, but the stock clearly remains focused more on growth than on yield.

Risk metrics show that Revvity Inc. carries a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80, giving the company solid liquidity and moderate leverage, according to MarketBeat. However, the shares exhibit a beta of 1.09, indicating slightly higher volatility than the broader market, and approximately 5.80% of the float is sold short with a days-to-cover ratio of 4.13, which points to a meaningful but not extreme level of skeptical positioning.

Upcoming conferences and earnings date on the calendar

Beyond the fundamental figures, Revvity Inc. has a busy investor-relations schedule in the near term. The company is slated to participate in the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026 and another Global Healthcare Conference on September 15, 2026, according to the company calendar compiled by MarketBeat. Such conferences typically provide management with a platform to update investors on strategic priorities and may influence sentiment around Revvity Inc. stock.

Looking slightly further ahead, the next earnings release for Revvity Inc. is currently estimated for October 26, 2026, based on the same calendar data from MarketBeat. With the fiscal year ending on December 31, 2026, this upcoming report will be closely watched for confirmation that the company can achieve its full-year guidance in the face of competitive pressures and modest revenue declines in recent quarters.

Life sciences and diagnostics portfolio as a driver

Revvity Inc. operates as a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets, offering reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support to customers worldwide, according to MarketBeat. Its offerings support applications ranging from drug discovery and genomics to environmental and food safety testing, industrial quality control and clinical diagnostics, giving the business exposure to diverse end markets and long-term structural demand for scientific tools.

A representative product area for Revvity Inc. is its reagents and consumables portfolio, which underpins many recurring-revenue relationships with pharmaceutical and biotechnology customers as well as academic research institutions. For investors, the critical question is how effectively the company can leverage this installed base to drive high-margin consumable sales and software-enabled services while navigating price competition and budget constraints among laboratories.

Revvity Inc. stock price and market metrics

On its primary listing at the New York Stock Exchange under the ticker RVTY, Revvity Inc. stock closed at 130.24 dollars on September 4, 2026, down 0.39 dollars or 0.30% on the day, with a trading volume of 1.18 million shares versus an average daily volume of 1.53 million shares, according to MarketBeat. Over the past 52 weeks, the shares have traded in a range between a low of 81.22 dollars and a high of 133.00 dollars, placing the current level near the upper end of that band.

At this price, Revvity Inc. commands a market capitalization of 14.53 billion dollars as of September 4, 2026, and the stock’s year-to-date performance shows a gain of 34.5% from 96.81 dollars on January 1, 2026 to 130.24 dollars in early September, according to MarketBeat. For investors watching Revvity Inc. stock, the combination of strong share-price appreciation, premium valuation, moderate dividend income and a cautious analyst consensus sets the stage for the next earnings report and upcoming conference appearances to act as potential catalysts for reassessment of the story.